A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Part of paid clinical trials in Sarasota, Florida.
- Sponsor
- Erasca, Inc.
- Study ID
- NCT06983743
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Metastatic Solid Tumors
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- ERAS-0015 — DRUGERAS-0015 Administered orally
- ERAS-0015 in combination — DRUGERAS-0015 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.
Study Details
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Key Dates
- Start date
- Jun 5, 2025
- Status verified
- Sep 2025
- Primary completion
- May 1, 2028
- Completion
- Dec 1, 2028
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: ERAS-0015 Monotherapy Dose Optimization.Escalating doses of ERAS-0015 administered orally.
- Experimental: ERAS-0015 Combination Dose OptimizationERAS-0015 administered orally with another investigational agent.
Primary Outcome Measure
Dose Limiting Toxicities (DLT) [ Time Frame: Study Day 1 up to Day 21 ]
Central Contacts
- Erasca Clinical Team Team+1-858-465-6511
- Les Brail, Study Director, PhD
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Florida Cancer Specalists | Sarasota | Florida | 34232 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | - |
| University of Texas at Tyler | Tyler | Texas | 75701 | - |
| NEXT Virginia | Fairfax | Virginia | 22031 | - |
Find similar trials in Sarasota, FL
Related Studies
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPHASE1/PHASE2 · Recruiting · Turning Point Therapeutics, Inc. · Duarte, California
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1/PHASE2 · Recruiting · Turning Point Therapeutics, Inc. · Los Angeles, California
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsPHASE1 · Recruiting · Incyte Corporation · Los Angeles, California
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsPHASE1 · Recruiting · Genentech, Inc. · Birmingham, Alabama